SCIENTIFIC BACKGROUND

ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53

Category:

Scientific Background

The hereditary breast/gynecological cancer panel tests for germline mutations that can cause a collection of different cancers that include breast cancer as well as cancers that start in the woman’s reproductive organs such as cervical, ovarian, and uterine. Hereditary breast and specific types of gynecological cancers are considered some of the most common inherited types of cancer.

 

PreSENTIA hereditary Breast/Gynecological cancer panel tests for numerous germline mutations that could cause Breast, Ovarian or Endometrial cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

 

Who is this test for?

You should get tested if you meet at least one of the criteria below:

You have a personal history of breast/gynecological cancers including ovarian, fallopian tube, and primary peritoneal cancer among others

You have been diagnosed with a breast/gynecological cancer before the age of 50

You have a family history of a breast/gynecological cancer

You belong in specific ancestry groups who are high risk for developing breast/gynecological cancers (e.g Ashkenazi Jewish)

You have a male relative diagnosed with breast cancer

 

How many genes are tested in this panel?

26 genes

 

How many hereditary cancer syndromes are associated with this panel?

12 Hereditary cancer syndromes are associated with this panel. These are:

• Ataxia-telangiectasia syndrome (ATM)

• Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)

• DICER 1 syndrome (DICER1)

• Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)

• Hereditary diffuse gastric syndrome (CDH1)

• Li-Fraumeni syndrome (TP53)

• Li-Fraumeni syndrome 2 (CHEK2)

• Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)

• MUTYH-associated polyposis syndrome (MUTYH)

• Peutz-Jeghers syndrome (STK11)

• Polymerase proofreading associated syndrome (POLD1, POLE)

• PTEN hamartoma syndrome (PTEN)

 

The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

BARD1, BRIP, MRE11, NBN, PALB2, RAD50, RAD51C, RAD51D, SMARCA4

 

Recommendations by professional bodies

Genetic testing is recommended when a family member has been previously diagnosed with a mutation in BRCA1/2 genes or any other related breast cancer genes

ESMO recommends (Cardoso et al., 2019) that genetic testing for germline BRCA1/2 mutations should be offered to breast cancer patients in high-risk groups. For example, patients with family history of breast, ovarian cancers, on patients who diagnosed with breast cancer before the age of 50, patients with personal history of ovarian cancer, breast cancer among others.

 

References and more information: 

All the above information was taken from ASCO, Centers for Disease Control and Prevention and NCCN

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 Aug 1;30(8):1194-1220. doi: 10.1093/annonc/mdz173. Erratum in: Ann Oncol. 2019 Oct 1;30(10):1674. Erratum in: Ann Oncol. 2021 Feb;32(2):284. PMID: 31161190.

GENES

ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53
How to order

LATEST ARTICLES

Neurodevelopmental disorders (NDDs) have diverse genetic origins, making diagnosis challenging. A new study analyzing over 1,100 pediatric patients f...

Read more

Colorectal cancer (CRC) remains one of the most prevalent and deadly cancers worldwide, with a significant number of cases presenting at an advanced ...

Read more

Carrier screening is a genetic test designed to identify whether an individual carries a gene with changes (mutations) associated with inherited diso...

Read more

Trisomy 13, also known as Patau syndrome, is a genetic condition in which cells in the body have three copies of chromosome 13 instead of two. The co...

Read more

The human brain develops through a complex series of events, with genes carefully regulating the formation of neurons and glial cells. A recent study...

Read more

Rare diseases affect between 300 and 400 million people worldwide – more than cancer and AIDS combined [1, 2], but despite this, many people face a...

Read more

Rosalind Elsie Franklin was a brilliant and meticulous research scientist whose interdisciplinary work made fundamental contributions to various area...

Read more

February, designated as Cancer Awareness Month, marks a time to reflect on the remarkable progress made in cancer research and to inspire hope for th...

Read more

Introduction Cardiovascular disease (CVD) is a major health issue as it remains a leading cause of death worldwide [1]. CVD is responsible for mor...

Read more

Antimicrobial resistance (AMR) is one of the most pressing global health threats, and accurate identification and surveillance of multidrug-resistant...

Read more